Option Care Enterprises Inc, Everett, WA

Is Option Care Enterprises Inc registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Option Care Enterprises Inc hold a Washington pharmacy license?

State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.

Has Option Care Enterprises Inc had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jun 30, 2020), 1 state referral letter (Jun 30, 2020) and 1 FMD-145 letter (Jun 30, 2020) for Option Care Enterprises Inc. State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Option Care Enterprises Inc
Location
Everett, WA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Jun 30, 2020
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 NAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 7 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Option Care Enterprises Inc, a 503A facility, with 3 dated actions.

Document
Jun 30, 2020State referral letterState Referral Letter Issued 06/30/2020Not linked by FDA
Jun 30, 2020FMD-145 letterFMD-145 Letter Issued 06/30/2020Not linked by FDA
Jun 30, 2020Warning letter close-outWarning Letter Close Out Issued 06/30/2020Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Option Care Enterprises, Inc., Everett, WA (FEI number 3009486960), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Feb 25, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009486960984089
Apr 16, 2012No Action Indicated (NAI)Drug Quality Assurance (Drugs)3009486960777046

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Feb 9, 2016 to Feb 25, 2016: 7 observations

Firm on the cover
Option Care Enterprises, Inc., 8120 Evergreen Way, CODE: Everett, WA 98203
FEI number
3009486960
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
22215 26th Ave SE Suite 210 Bothell, WA 98021, P:
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, A) Your firm does not investigate the impact of positive environmental microbiological results on sterile injectable drug products. SOP P-165 "Environmental Monitoring" Revised date 1210412015, section Action Steps For Positives Samples, states in part: "***If the results of the microbial identification REDACTED (b) (4). REDACTED (b)(4) microorganisms include gram-negative rods, coagulases positive staphylococcus, molds, and yeasts***". For example, there was no investigation performed after the following gram-negative rods were identified in the ISO 5 and ISO 8 areas:

1) On June 16, 2015 after surface sampling of the REDACTED (b) (4) one gram negative rod was identified as Acinetobacter baumannii.

,..------- 2) On Dec 15, 2015 after air sampling REDACTED (b) (4), one gram negative rod was identified as Brevundimonas intermedia.

B) Your environmental monitoring procedure SOP P-165 "Environmental Monitoring" Revised date 12/04/2015 is deficient in that there is no scientific rationale to support the frequency of testing:

Add Continuation Page ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically, A) On February 9, 2016 the following inadequate aseptk techniques were observed:

!bl (6), 1) Technician REDACTED b6, b7C was observed touching non-sterile items such as the inner liner of a waste receptacle and a metal cart. Technician REDACTED b6, b7C then moved in and out of the ISO 5 hood without always sanitizing or changing her gloves while handling components used in the filling of Ertapenem 1g/100mL NS Eclipse, Batch # REDACTED b6, b7C.

2) Operators were observed working deep inside the ISO 5 hoods with parts of their non-sterile garbing materials exposed inside the ISO 5 hoods. For example,

(b)(6f(6~ i. Technician (7)(C) Jwas observedr -(of(4) for the preparation ofTPNf (o) (4) ~atch #~b)(6),(b)(7)(C)j with the sleeve ofber non-sterile lab coat exposed under the ISO 5 hood (15) (4) I

(b)(6), ii. Technician REDACTED b6, b7C was observed manipulating components for the preparation of Ertapenem 1g/100mL NS Eclipse, Batch #REDACTED b6, b7C with the sleeves of her non-sterile lab coat exposed under the ISO 5 hood REDACTED b4. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the

duties they perform.

Specifically, the attire worn by operators on February 9, 2016 during the filling of sterile injectable drugs TPN

REDACTED (b) (4), Batch # REDACTED (b)(6),(b)(7)(C) and Ertapenem 1g/100mL NS Eclipse, Batch # (b)(6),(b)(7)(C) was inadequate as follows:

A) REDACTED (b)(4) Technicians were observed working in the ISO 5 hoods REDACTED (b) (4) wearing disposable non-sterile head covers, non-sterile surgical masks, non-sterile lab coat, and non-sterile shoes.

B) The non-sterile surgical masks and non-sterile head covers worn by the REDACTED (b) (4)Technicians did not provide adequate coverage to the forehead, neck, or face. The Technicians were also not wearing protective eyewear.

C) The firm SOP P-128 "Proper Attire, Garbing and Hand Washing for Clean Room Personnel", Revised date

10/26/2015, states in part: " ***Clean room attire that includes scrubs and shoes., REDACTED (b) (4) was not followed. Technician REDACTED b6, b7C confrrmed that the operators are allowed REDACTED (b) (4). ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, A) Non-sterile REDACTED (b)(4) are used to clean the ISO 5 hoods and ISO 7 clean room. On February 9, 2016, Technician (b)(6), (b)(7)(C) was observed spraying the inside surface of the ISO 5 REDACTED (b)(4) with sterile REDACTED (b)(4) and then wiping the surface with non-sterile REDACTED (b)(4) prior to and during the filling of Ertapenem 1g/100mL NS Eclipse, Batch REDACTED (b)(7)(C).

B) On February 9, 2016 apparent staining were observed on the metal grates covering the HEPA filter of the ISO 5 hoods REDACTED (b) (4) during the filling of TPN REDACTED (b) (4) Batch# REDACTED (b) (7),(b)(7)(C) Also, apparent staining were observed on the metal grates covering the pre-filters of the ISO 5 hood REDACTED (b)(4) during the filling of Ertapenem 1g/100mL NS Eclipse, Batch # REDACTED (b)(6),(b)(7)(C)

Observation 5

The separate or defined areas necessary to prevent contamination or mix-ups are deficient.

Specifically, on February 9, 2016, the operators failed to follow your sterile compounding and aseptic technique procedures during the filling of sterile injectable drugs TPN REDACTED (b) (4) Batch # REDACTED (b)(6),(b)(7)(C) and Ertapenem 1 g/100mL NS Eclipse, Batch # REDACTED (b)(6),(b)(7)(C) as follows:

Add Continuation Page

J;;YE1JI';TURE 8vt K

OF THIS

PAGE Y.rPo 6PD

A) We observed a REDACTED (b) (4) that is located between ISO 5 hoods REDACTED (b) (4) In the ISO 7 clean room. The REDACTED (b) (4) SOP P-125, "Sterile Compounding Environment Procedures" states in part: "** * REDACTED (b)(4).

B) During REDACTED (b) (4 ) were not protected from potential lint shedding. SOP P-132, "Aseptic Technique Procedures" states in part: REDACTED (b) (4 ).

Observation 6

Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically, sterility testing is not performed on each batch, or representative batches of filled sterile injectable drug products. For example, no sterility testing is performed on batches of sterile-to-sterile filled, preservative free, drug products such as: (1) Ertapenem 1gm/100 mL (BUD 7 days at refrigerated condition); (2) Total Parenteral Nutrition, REDACTED (b) (4 ) (BUD 9 days at refrigerated condition); (3) Ceftriaxone 2 gm/20 mL (BUD 9 days at refrigerated condition); and (4) Cefazolin 2 gm/20 mL (BUD 9 days at refrigerated condition).

Md Contin.uatioh P.age

Observation 7

The drug product is not identified with a lot or control number that permits the determination of the history of the manufacture and control of the batch.

Specifically, the firm does not have a procedure describing the storage and reuse of REDACTED (b) (4 ). T he REDACTED (b) (4). The prescription number and the nu mber of un

its of REDACTED (b) (4) re not a lways documented to ensure traceability of individual units. On February 9, 2016, we observed the following ster ile injectable drug products stored in a bin labeled as “REDACTED (b)(4)” in a refriger ator located in the ISO 8 anteroom:

(b) (4) MEDS OBSERVED IN THE ISO 8 ROOM REFRIGERATOR

Table: REDACTED (b)(4) MEDS OBSERVED IN THE ISO 8 ROOM REFRIGERATOR

PRODUCT QUANTITY FILLED DATE EXPIRATION DATE BEYOND USE DATE Cefazolin 2 gm/20 mL REDACTED (b)(4) X 20 mL syringes 2/1/2016 2/10/2016 9days Cefazolin 2 gm/20 mL REDACTED (b)(4) X 20 mL syringes 2/2/2016 2/11/2016 9 days Vancomycin 1.75 gm/400 mL REDACTED (b)(4) X 400 mL units 2/2/2016 2/11/2016 9 days NS Eclipse Buffered Lidocaine 1% 10 mg/mL REDACTED (b)(4) X 22.2 mL vial 2/4/2016 2/11/2016 7 days Ertapenem 1 gm/100 mL NS Eclipse REDACTED (b)(4) X 100 mL unit 2/8/2016 ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Washington are not checked: the Department of Health’s open dataset on data.wa.gov lists individual credentials but not pharmacy licenses, and its enforcement column has been removed for now; the department’s provider search is an interactive search, which this index does not use.

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.